Table 1

A summary table of the meta-analysis

Study	Year	Country	Diseases	Case no	Stage	Sample	Assay	Cut-off value	HR	Follow-up (months)	Type of miR-17 detection
Chen et al 37	2012	China	HCC	120	I–IV	Tissue	qRT-PCR	Median	RR	46	miR-17–5p
Qun et al²⁷	2013	China	Lung cancer	221	I–IV	Tissue	qRT-PCR	Median	Given	50	miR-17
Li et al 41	2014	China	Osteosarcoma	117	I–III	Tissue	qRT-PCR	Median	Given	44	miR-17
Lu et al 35	2012	China	Glioma	108	I–IV	Tissue	qRT-PCR	Mean	RR	60	miR-17
Xi et al 42	2015	China	T-cell lymphoblastic lymphoma	57	III, IV	Tissue	qRT-PCR	Median	Given	Up to 13 years	miR-17
Yu et al 40	2012	China	Colon cancer	48	I–IV	Tissue	qRT-PCR	Median	Given	5–66	miR-17
Manuel et al³⁹	2011	Spain	Gastrointestinal cancer	38	I–IV	Tissue	qRT-PCR	Mean	Given	38	miR-17
Robaina et al 38	2016	Brazil	Burkitt lymphoma	41	I–IV	Tissue	ISH	Median	Given	69	miR-17
Xu et al 36	2014	China	Oesophageal squamous cell carcinoma	105	I–IV	Tissue	qRT-PCR	Mean	Given	52	miR-17
Jun et al²⁶	2010	Japan	Pancreatic cancer	80	I–IV	Tissue	qRT-PCR	Median	Given	60	miR-17–5p
Wang et al⁴³	2011	China	Gastric cancer	65	I–IV	Serum	qRT-PCR	Median	Given	36	miR-17–5p
Zheng et al 34	2013	China	HCC	96	I–IV	Serum	qRT-PCR	Median	Given	NG	miR-17–5p

HCC, hepatocellular carcinoma; ISH, in situ hybridisation; miR-17, microRNA-17; NG, not given; OS, overall survival; qRT-PCR, quantitative real-time PCR; RR, risk ratio.